Back to Market Feed

Product Information

KISQALI 600 MG DAILY DOSE is a brand product labeled by Novartis Pharmaceuticals Corporation, priced at $289.7167 per EA under NDC 00078087463. Its NADAC has been published 88 times since Dec 18, 2024.

FDA first approved this application on Mar 13, 2017.

KISQALI 600 MG DAILY DOSE

ribociclib
$289.7167per EA

Strength

200 mg/1

NDC

00078087463

Classification

Brand

Dosage Form

TABLET, FILM COATED

Route

ORAL

Effective Date

4/22/2026

Active Ingredients

RIBOCICLIB SUCCINATE

Approval Type

New Drug (NDA)

FDA Application

NDA209092

FDA Approved

3/13/2017

On Market Since

3/13/2017

Pharmacological Classes

Cytochrome P450 3A Inhibitors
Kinase Inhibitor
Kinase Inhibitors

Price Statistics

The NADAC for KISQALI 600 MG DAILY DOSE has been published 88 times since Dec 18, 2024, and over the history we have for it it has risen 6.9%. The table below summarizes its recorded NADAC range and movement.

Current price$289.7167 per EA
All-time high$292.6762 (Dec 10, 2025)
All-time low$270.9964 (Dec 18, 2024)
52-week high$292.6762
52-week low$289.7167
Median price$292.6762
Average price$290.3785
Largest weekly change+8.0% (Jan 22, 2025)
Weeks tracked88
Tracking sinceDec 18, 2024

Price History

1W

0.0%

1M

0.0%

3M

0.0%

6M

-0.3%

1Y

-1.0%

3Y

N/A

5Y

N/A

All

+6.9%

Generic Alternatives

The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Lowest-Cost Alternatives

1 alternative • Same active ingredient

KISQALI 400 MG DAILY DOSE
Brand
00078086742•Novartis Pharmaceuticals Corporation
$346.9469
+20% more

Related Drugs

Same classification

MYRBETRIQ ER 8 MG/ML SUSP
Brand
00469502099•Astellas Pharma US, Inc.
$2.2069
per ML
KALETRA 80 MG-20 MG/ML SOLN
Brand
00074395646•AbbVie Inc.
$3.1186
per ML
KATERZIA 1 MG/ML SUSPENSION
Brand
52652500101•Azurity Pharmaceuticals Inc.
$4.2005
per ML
KALETRA 200-50 MG TABLET
Brand
00074401412•AbbVie Inc.
$8.3041
per EA
KALETRA 200-50 MG TABLET
Brand
00074679922•AbbVie Inc.
$8.3041
per EA
NORVIR 100 MG TABLET
Brand
00074234030•AbbVie Inc.
$8.3281
per EA
EXFORGE HCT 5-160-25 MG TAB
Brand
00078056015•Novartis Pharmaceuticals Corporation
$8.4511
per EA
EXFORGE HCT 10-160-12.5 MG TAB
Brand
00078056115•Novartis Pharmaceuticals Corporation
$8.4532
per EA
EXFORGE HCT 5-160-12.5 MG TAB
Brand
00078055915•Novartis Pharmaceuticals Corporation
$8.5559
per EA
NORVASC 5 MG TABLET
Brand
00069153068•Pfizer Inc.
$8.6976
per EA

Frequently asked questions

What is the NADAC price of KISQALI 600 MG DAILY DOSE?

The current National Average Drug Acquisition Cost (NADAC) for KISQALI 600 MG DAILY DOSE, manufactured by Novartis Pharmaceuticals Corporation, is $289.7167 per EA (NDC 00078087463), effective Aug 19, 2026.

How has the price of KISQALI 600 MG DAILY DOSE changed over time?

Over the history we have for it, the NADAC for KISQALI 600 MG DAILY DOSE has risen 6.9%. It has been tracked across 88 weekly CMS publications since Dec 18, 2024.

What are the highest and lowest recorded NADAC prices for KISQALI 600 MG DAILY DOSE?

Since Dec 18, 2024, the NADAC for KISQALI 600 MG DAILY DOSE has ranged from a low of $270.9964 (Dec 18, 2024) to a high of $292.6762 (Dec 10, 2025), with a median of $292.6762 per EA.

Are there cheaper alternatives to KISQALI 600 MG DAILY DOSE?

1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as KISQALI 600 MG DAILY DOSE in a comparable dosage form, but none are currently priced below it.

Who manufactures KISQALI 600 MG DAILY DOSE?

KISQALI 600 MG DAILY DOSE (NDC 00078087463) is labeled by Novartis Pharmaceuticals Corporation, and CMS classifies it as a brand product.